Background and Purpose-Progression of asymptomatic carotid artery stenosis (ACAS) in patients with >50% luminal narrowing is considered a potential risk factor for ischemic stroke; however, subclinical molecular biomarkers of ACAS progression are lacking. Recent studies suggest a regulatory function for several microRNAs (miRNAs) on the evolution of carotid plaque, but its role in ACAS progression is mostly unknown. The aim of our study was to investigate a wide miRNA panel in peripheral blood exosomes from patients with ACAS to associate circulating miRNA expression profiles with stenosis progression. Methods-The study included 60 patients with ACAS carrying >50% luminal narrowing. First, miRNA expression profiles of circulating exosomes were determined by Affymetrix microarrays from plasma samples of 16 patients from the cohort. Second, those miRNAs among the most differentially expressed in patients with ACAS progression were quantified by real-time polymerase chain reaction in a separate replication cohort of 39 subjects within the patient sample. Results-Our results showed that ACAS progression was associated with development of stroke. , and miR-24-3p presented significant higher expression in those patients with ACAS progression. Conclusions-In conclusion, our study supports that specific circulating miRNA expression profiles could provide a new tool that complements the monitoring of ACAS progression, improving therapeutic approaches to prevent ischemic stroke.
C
arotid artery stenosis is an important risk factor for ischemic neurological events, being responsible for ≈10% ischemic strokes. 1 Such atherosclerotic pathology can proceed silently 2 from the simple thickening of the intima-media layers to the symptomatic stenosis. In these terms, the benefit of preventive carotid surgery in patients with asymptomatic carotid artery stenosis (ACAS) is increasingly controversial because of the moderate risk of stroke with appropriate medical treatment (including statins and antiplatelet drugs). 3 Thereby, identifying those patients at higher risk of developing future neurological events could help to target intensive therapy or invasive strategies more appropriately. 4 Among several clinical factors, progression of ACAS with >50% luminal narrowing is considered a potential marker of higher stroke risk, even better than the degree of stenosis. 2, 5 In fact, stenosis progression measured by Doppler ultrasound has been reported as a predictor of ipsilateral vascular events. 2, 6 However, the stenosis progression event is not well established in patients with ACAS, and subclinical molecular biomarkers, determining which asymptomatic stenosis will remain stable or progress until becoming symptomatic, are lacking. Recent studies suggest a potential regulatory function for several microRNAs (miRNAs) on dysfunctional endothelium, contributing to the evolution of carotid plaque toward growth, instability, and rupture. 7 Such previous studies took a targeted approach to miRNA analysis on tissue from the carotid plaque itself. Nonetheless, the role played by miRNAs in ACAS progression is mostly unknown and a discovery-based approach to a circulating miRNA profile in peripheral blood, as a biomarker of stenosis progression, has not yet been investigated. In these terms, it is known that miRNAs can be selectively released from vascular or blood cells, as the cargo in exosomes, into peripheral blood circulation. 8, 9 In contrast to other extracellular vesicles, exosomes are thought to be released by living cells through an active process in response to environmental perturbations, in order to transfer its miRNA content into recipient cells, thus playing a role in cell-to-cell communication. 9, 10 We reasoned that unstable carotid plaques could trigger a selective release of miRNAs in exosomes by vascular and peripheral blood cells, which could contribute to the process of carotid stenosis.
Therefore, we aimed to decipher whether miRNA profiles of circulating exosomes could be considered as novel noninvasive biomarkers of ACAS progression to recognize high-risk patients of embolic stroke, in whom preventive carotid revascularization would be formally indicated. For this purpose, we determined ACAS progression by serial Doppler ultrasounds, and we analyzed a wide miRNA panel in circulating exosomes from patients with ACAS (>50% luminal narrowing), in order to associate miRNA expression profiles with progression of carotid stenosis.
Methods

Study Design
The study included 60 consecutive patients with ACAS carrying >50% luminal narrowing. All patients were recruited between 2011 and 2014 from the Vascular Pathology Outpatient Service and the Stroke Unit of the Neurology Department at the Hospital Universitario y Politécnico La Fe (Valencia, Spain). Initially, a discovery microarray analysis was performed on a subset of 16 patients (Table I in the online-only Data Supplement) followed by a polymerase chain reaction (PCR) replication analysis in a separate cohort of 39 subjects (Table II in the online-only Data Supplement) within the patient sample. Five patients did not provide high-quality plasma and RNA samples, which was a limiting criterion for the molecular study inclusion. The main characteristics and outcomes of patients are shown in Tables 1 and 2, respectively. Demographic data, vascular risk factors, and previous ischemic stroke events were recorded. Patients were eligible if they had >50% stenosis of any internal carotid artery (ICA) and had not had any established or transient cerebral or retinal symptom in the preceding 6 months. 11, 12 Medical treatment was in accordance with universally accepted good practice guidelines, with special emphasis on management of cardiovascular risk factors. All patients were carefully followed in our outpatient clinic. Transient ischemic attack (TIA), ischemic stroke, hemorrhagic stroke, myocardial infarction, peripheral vascular procedure or amputation, and other events were recorded in each visit. Death was classified as vascular death (including stroke, myocardial infarction, sudden death and death from heart failure, aortic dissection, or pulmonary embolism) and other causes of death.
The ultrasonographic findings for each carotid were classified as: (1) normal, (2) stenosis <50%, (3) stenosis 50% to 70%, (4) stenosis >70%, and (5) occlusion. The thresholds used in our laboratory to evaluate carotid in-stent restenosis are summarized elsewhere. 13 The follow-up of patients included clinical visits and carotid ultrasound studies every 6 months, during 2 years, to detect possible vascular events and to assess stenosis progression, respectively. Patients were classified into 2 groups according to Doppler ultrasound studies: patients with progression of ACAS (when luminal narrowing of any stenotic carotid artery was incremented from >50% to >70% or from >70% to occlusion, during the study) or patients without progression. At time of inclusion, a peripheral blood sample from each patient was collected in citrate Vacutainer tubes.
The Isolation of circulating exosomes followed by RNA extraction was performed from plasma samples using the exoRneasy Serum/ plasma Midi Kit (Qiagen) and purified Torulla yeast RNA (Ambion; Life Technologies) at 0.2 µg/mL plasma was added, as a carrier, to improve the RNA yield increase. RNA purity and concentration were evaluated spectrophotometrically using NanoDrop ND-2000 (ThermoFisher). In addition, quality and integrity of RNA were assessed by the Agilent Small RNA kit for low-molecular weight RNA in a microfluidics-based platform Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara), before processing expression microarrays, at the Genomics Unit IIS La Fe.
MiScript Reverse Transcription Kit (Qiagen GmbH, Hilden, Germany) with miScript HiSpec Buffer was used to transcribe RNA into cDNA for subsequent quantification of mature miRNAs by quantitative PCR, according to the manufacturer' s protocol.
MicroRNA Analysis by Expression Microarrays
MiRNA expression profiles were determined in 16 RNA samples (10 from patients with ACAS progression and 6 from patients without progression), using the Affymetrix platform available in the Genomics Unit IIS La Fe. For that purpose, microarray GeneChip miRNA 4.0 that contains 6600 human noncoding RNA probes, including 2578 mature miRNAs, 2025 premiRNAs, and 1996 RNAs CDBOX, H/ACABOX, snoRNAs and scaRNAs, based on miRBase version 20 (http://mirbase.org), was used. A total amount of 8 µL of RNA eluted from Qiagen exosome kit was directly labeled avoiding any amplification process with FlashTag miRNA kit (Genisphere), according to manufacturer's procedures. The RNAs were hybridized [PCA] ) and nonhierarchical clustering discovering tools were applied for testing of batch effects, sample association, similar expression profiles, and outliers. Statistical tests for multiple data were used to detect differences between groups and define expressed molecules: ANOVA and hierarchical clustering. The software allowed setting selection filters from ANOVA lists based on fold change and P values associated to each molecule.
Quantification of MicroRNA Expression by PCR
The miRNAs achieving higher differences in expression according to microarray results (±1.5 fold change; P<0.05) were chosen for next PCR replication on the basis of relevance to the most differentially and significantly expressed (±1.7 fold change; P<0.025) and also to the existence of previous publications linking miRNAs with several processes (such as inflammation or angiogenesis) that could invoke major significance at the dysfunctional endothelium, leading to carotid plaque progression.
14 MiRNAs were quantified by real-time PCR in available RNA samples from the overall patients, using the miScript SYBR Green PCR Kit (Qiagen GmbH) and miScript Primer assays: MS00031668 for miR-27b-3p, MS00006741 for miR-199a-5p, MS00008764 for miR-151a-5p, MS00006552 for miR-24-3p, MS00031647 for miR-23b-3p, MS00007609 for miR-222-3p, MS00031241 for miR103a-3p, MS00003444 for miR-130a-3p, MS00003535 for miR146a-5p, MS00004032 for miR-361-5p, MS00003857 for miR-221-3p, MS00029239 for miR-26a-5p, MS00007602 for miR-199b-3p, MS00031514 for miR-18a-5p, and MS00043624 for miR-638 (Qiagen GmbH). According to signal data from microarrays, miR-638 was used as reference miRNA for normalization because it showed the most homogeneous expression levels, in terms of coefficient of variance, in our samples (mean probe signal: 7.4; SD: 0.3; CV: 3.7%).
All quantitative PCR assays were performed in a ViiA 7 Real-Time PCR System (Applied Biosystems). The PCR program consisted of an initial Taq activation at 95 °C for 15 minutes, followed by 40 cycles of denaturation at 94 °C for 15 seconds, and finally, annealing at 55 °C for 30 seconds and extension at 70 °C for 34 seconds. The 2 −(∆∆Ct) method 15 was used to estimate miRNA expression in patients with ACAS progression relative to patients without progression. All data were normalized using endogenous miR-638 expression, and only those data with a Ct value <30 for miR-638 were included in the evaluation.
Statistic Analysis
Differences in the distribution of categorical variables were analyzed using the χ 2 test, applying Fisher's exact test when required. The Mann-Whitney U or Kruskal-Wallis test was used to analyze continuous variables for data that failed the normality test. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by logistic regression. A statistical correction of the ORs was applied according to previous publications 16, 17 when required. Appropriate adjustments for multiple comparisons were performed by using the false discovery rate method. 18 All P values reported were 2 sided, and a P value <0.05 was considered significant. Statistical analyses were performed using the SPSS version 17.0 statistical package (Chicago, IL).
Results
Patient Characteristics
Distribution of ACAS in our patients was 27 (45%) in right ICA, 30 (50%) in left ICA, and 3 (5%) in both ICA. One patient had a concomitant contralateral ICA occlusion and 15 patients (25%) carried a contralateral ICA stent.
A total of 19 patients (31.7%) from the ACAS cohort showed stenosis progression after 2-year follow-up (15.8% annual rate). ACAS progression, detected by serial Doppler ultrasounds, was associated with development of ischemic stroke or TIA in patients after inclusion (100% versus 26.8%; ORs, 24.1; 95% CI, 1.2-474.2; P=0.036). None of the other clinical or biological features showed significant differences among patients with or without ACAS progression (Table 3) .
Furthermore, development of ischemic stroke or TIA in patients after inclusion was associated with vascular death event (40% versus 3.6%; ORs, 18; 95% CI, 1.8-175.8; P=0.013).
MicroRNA Expression Profile According to the Progression of Asymptomatic Carotid Artery Stenosis
PCA showed a different distribution of the RNA samples, based on its miRNA expression profiles, from patients with ACAS progression compared with the samples from patients without progression ( Figure 1A ). The hierarchical clustering clearly identified a different miRNA expression profile in RNA samples from patients with ACAS progression compared with the patients without progression ( Figure 1B) .
By applying ±1.5-fold change and P<0.05 criteria to the ANOVA test, a total of 59 miRNAs were differently expressed when progression of ACAS in patients (Table III in 
MicroRNA Expression by PCR and Its Association With Clinical and Biological Characteristics
The expression levels of miR-199b-3p, miR-199a-5p, miR-18a-5p, miR-27b-3p, miR-130a-3p, miR-146a-5p, ) confirmed results from expression microarrays in which patients with ACAS progression showed a trend to overexpress these miRNAs relative to the patients without progression, except the miR-18a-5p which tended to be lower expressed in patients with ACAS progression (Figure 2) .
Patients with ACAS progression presented miRNA expression levels significantly higher than patients without progression in case of miR-199b-3p (median, 
Discussion
The current study presents a survey of ACAS, in patients with >50% luminal narrowing, to associate circulating miRNAs as subclinical biomarkers of stenosis progression. The results identified a different miRNA expression profile in those patients with ACAS progression.
In our patient series, during a 2-year follow-up period, the annual rate of stenosis progression was 15.8%. Indeed, stenosis progression may occur in 5% to >20% of patients with ACAS.
11 First, our results showed that patients with ACAS progression had increased probability of stroke or TIA during follow-up. This finding supports previous studies that demonstrated that progression of ACAS with >50% luminal narrowing is considered a potential marker of higher stroke risk. 6, 18 Furthermore, as expected by previous knowledge, 19 the event of later ischemic stroke or TIA was associated with vascular death in our patients.
The current challenge is to target groups at high risk of stroke among patients with ACAS >50% to 70%. Therefore, second we investigated miRNAs that could be associated with ACAS progression and thereby could be linked to the development of ischemic neurological events. Previous studies of carotid disease had analyzed miRNAs in tissue from the carotid plaque itself, taking a targeted miRNA approach. 7 In contrast, our study aimed a novel miRNA discoverybased approach to identify circulating miRNAs in peripheral blood as novel biomarkers of stenosis progression. In addition, our study was based on previous publications that recognize that circulating exosomes are key players in atherosclerosis because of its emergent role in mediating cellto-cell communication, particularly through their delivered miRNA content between blood cells and vascular cells. 9 In these terms, we identified a differential miRNA expression profile in circulating exosomes from patients with ACAS progression compared with that obtained in patients without progression, which was confirmed by PCR. All of these miRNAs had previously been related with processes such as inflammation, [20] [21] [22] angiogenesis, [23] [24] [25] or endothelial and vascular smooth muscle cell differentiation, [26] [27] [28] [29] [30] [31] which invoke major significance at the dysfunctional endothelium leading to atherosclerotic plaque growth, instability, rupture, and subsequent cerebrovascular events.
14 Indeed, miR-199b had been involved in endothelial cell differentiation and angiogenesis through the vascular endothelial growth factor signaling. 23 Also, miR-130a and miR-27b had been identified as proangiogenic miRNAs, 24 and the miR-221/222 cluster had been proposed as a regulator of vascular smooth muscle cell and endothelial cell biology, contributing to endothelial dysfunction and vascular remodeling and driving to neointimal hyperplasia in response to vascular injury. 27, 28 Similarly, miR24 had been involved in vascular smooth muscle cell migration and proliferation. 30 Regarding previous studies in carotid plaques, miR146a had been found upregulated in atherosclerotic plaques obtained from human carotid arteries, 32 and miR-221 had been detected significantly overexpressed in symptomatic versus asymptomatic human carotid plaques. 7 Accordingly, we showed both miRNAs presented higher expression in circulating exosomes from patients with ACAS progression compared with the patients without progression, demonstrating a statistical significance in case of miR-221-3p. However, our results differed from other miRNAs that previous studies had identified differentially expressed on unstable plaques, such as miR-100, miR-133a, or miR-145. 7 We suggested that miRNA ) showed that patients with ACAS progression overexpressed the miR-199b-3p, miR-130a-3p, miR-146a-5p, miR-221-3p, miR-361-5p, miR-26a-5p, miR-27b-3p, miR-103a-3p, miR-151a-5p, miR-199a-5p, miR-222-3p, miR-23b-3p, and miR-24-3p relative to the median expression of such miRNAs in patients without ACAS progression, respectively, with a median increase between 1.23 and 3.76 times (P<0.05). However, patients with ACAS progression showed lower expression levels for the miR-18a-5p relative to the patients without progression, with a median decrease of 0. profiles in exosomes from peripheral blood could not overlap exactly with those detected in carotid plaques, because miRNA content in circulating exosomes could derive from surrounding vascular and peripheral blood cells in response to the environmental perturbations in carotid arteries.
Hence, considering previous publications and according to our results, we suggest that the circulating miRNA expression profile that we identified in patients with ACAS could serve as a subclinical biomarker for stenosis progression, mainly the miR-199b-3p, miR-24-3p, miR-221-3p, miR-27b-3p and miR-130a-3p, which showed the most consistent results. Interestingly and closely related to our findings, miR-130a had been detected significantly upregulated in serum samples from patients with Moyamoya disease, a cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. 33 It is already known that miR-130a is a proangiogenic miRNA since antagonizes the inhibitory effects of several genes, as GAX or HOXA5, on endothelial cell growth. 34 Moreover, just like miR-103a, miR-130a-3p mediates KLF4 gene expression, 35 which could promote carotid atherosclerosis and vascular inflammation because, as previously described, KLF4 suppression increases monocyte adhesion to endothelial cells and lesional macrophage accumulation. 20 Regarding several limitations of our study, the patient series was not enough larger to analyze a potential association between miRNA expression levels and the event of ischemic stroke. However, we tried to circumvent this inconvenience by choosing the stenosis progression as a surrogate marker of stroke. Also, although our study did not include healthy controls, we considered as controls for ACAS disease those patients who did not develop stenosis progression during follow-up.
In conclusion, our study suggests the role of a specific circulating miRNA expression profile as a noninvasive biomarker of ACAS progression. However, further studies in larger series of patients would be necessary to confirm our findings.
Summary
Patients with ACAS progression had increased probability of stroke or TIA during follow-up. A specific circulating miRNA expression profile was differentially expressed in these patients. In particular, miR-199b-3p, miR-130a-3p, miR-24-3p, miR-221-3p, and miR-27b-3p showed quantitative expression levels significantly higher in patients with ACAS progression. These findings suggest the role of specific circulating miRNA expression profiles as noninvasive biomarkers of carotid stenosis progression, which could provide in future a new tool for ACAS monitoring, improving preventive therapeutic approaches for ischemic stroke in patients. However, further studies in larger series of patients would be necessary to confirm these findings.
